ArticleBriefings in bioinformatics2021
Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus.
Article in Briefings in bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Cepharanthine Inhibits Influenza A Virus Infection by Blocking Viral Attachment to Host Cells.Journal of medical virology · 2026Article
- T-Cell Immune Dysfunction and Progression to Severe COVID-19 in Asthma Revealed by Single-Cell RNA Sequencing.Tuberculosis and respiratory diseases · 2026Article
- Cepharanthine InhibitsMicroorganisms · 2025Article
- Bisbenzylisoquinoline alkaloids inhibit influenza virus replication by disrupting endosomal acidification.Virology journal · 2025Article
- Integration of network pharmacology, transcriptomics, and experimental verification to investigate the mechanism of action of cepharanthine hydrochloride against prostate cancer.Scientific reports · 2025Article
- Antiviral Activity of 1-Deoxynojirimycin Extracts of Mulberry Leaves Against Porcine Epidemic Diarrhea Virus.Animals : an open access journal from MDPI · 2025Article
- A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization.Chinese medicine · 2025Review
- Association of plasma microRNAs with COVID-19 severity and outcome.Journal, genetic engineering & biotechnology · 2024Article
- Identification of cepharanthine as an effective inhibitor of African swine fever virus replication.Emerging microbes & infections · 2024Article
- Review
- Cepharanthine analogs mining and genomes of Stephania accelerate anti-coronavirus drug discovery.Nature communications · 2024Article
- CAP-RNAseq: an integrated pipeline for functional annotation and prioritization of co-expression clusters.Briefings in bioinformatics · 2024Article
- Interaction between coronaviruses and the autophagic response.Frontiers in cellular and infection microbiology · 2024Review
- Research progress on pharmacological effects and mechanisms of cepharanthine and its derivatives.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China.European journal of medicinal chemistry · 2023Review
- Pharmacological Activity of Cepharanthine.Molecules (Basel, Switzerland) · 2023Review
- Unraveling the mechanism of action of cepharanthine for the treatment of novel coronavirus pneumonia (COVID-19) from the perspectives of systematic pharmacology.Arabian journal of chemistry · 2023Article
- Novel insight into the underlying dysregulation mechanisms of immune cell-to-cell communication by analyzing multitissue single-cell atlas of two COVID-19 patients.Cell death & disease · 2023Article
- Current status and future challenges in extraction, purification and identification of Cepharanthine (a potential drug against COVID-19).Separation and purification technology · 2023Review
- Neutrophil autophagy and NETosis in COVID-19: perspectives.Autophagy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiviral therapies targeting the pandemic coronavirus disease 2019 (COVID-19) are urgently required. We studied an already-approved botanical drug cepharanthine (CEP) in a cell culture model of GX_P2V, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related virus. RNA-sequencing results showed the virus perturbed the expression of multiple genes including those associated with cellular stress responses such as endoplasmic reticulum (ER) stress and heat shock factor 1 (HSF1)-mediated heat shock response, of which heat shock response-related genes and pathways were at the core. CEP was potent to reverse most dysregulated genes and pathways in infected cells including ER stress/unfolded protein response and HSF1-mediated heat shock response. Additionally, single-cell transcriptomes also confirmed that genes of cellular stress responses and autophagy pathways were enriched in several peripheral blood mononuclear cells populations from COVID-19 patients. In summary, this study uncovered the transcriptome of a SARS-CoV-2-related coronavirus infection model and anti-viral activities of CEP, providing evidence for CEP as a promising therapeutic option for SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.